Exploring the Possibilities of Microbial Genomes in Drug Development
In a significant breakthrough, researchers at the University of California, San Diego (UC San Diego) have developed a new synthetic biology technology that promises to unlock the drug discovery potential of countless new and mysterious microbes.
This innovative technology, based on transformation-associated recombination (TAR) cloning, enables the expression and activation of otherwise silent biosynthetic gene clusters (BGCs) from microorganisms like Streptomyces. These microorganisms are known producers of bioactive secondary metabolites, including the promising natural product, taromycin A.
Taromycin A, with its potent activity against drug-resistant pathogens such as MRSA (methicillin-resistant Staphylococcus aureus), could play a crucial role in combating antibiotic-resistant infections. By engineering and designing optimized host bacteria, or microbial "chassis" strains, the UC San Diego team can efficiently produce natural products encoded by these gene clusters, including compounds like taromycin A.
The genetic platform designed by the researchers is uniquely efficient in producing natural product molecules from uncharacterized gene collections. The study, supported by grants from the National Institutes of Health, focused on the taromycin gene cluster, which shares a high degree of similarity with the biosynthesis pathway of daptomycin, a clinically approved antibiotic.
The research team, led by principal investigator David Gonzalez, includes Kazuya Yamanaka, Kirk Reynolds, Roland Kersten, Katherine Ryan, and Pieter Dorrestein. UC San Diego's Technology Transfer Office has filed patent applications on this process and on the taromycin antibiotics, which are available for licensing.
This development marks a significant step forward in the fight against antibiotic resistance, accelerating the discovery of new drug candidates and opening up a world of possibilities for the exploration of new and mysterious microbes.
[1] Reference: (Citation needed)
- This new synthetic biology technology developed at UC San Diego has the potential to revolutionize the medical-conditions sector, as it may lead to the discovery of countless drugs to combat various health-and-wellness issues, including antibiotic-resistant infections like MRSA.
- The finance industry may soon see significant investments in the science sector, particularly in the healthcare-and-wellness industry, due to the promising prospects of this TAR cloning technology and its potential impact on the discovery of new drugs.
- The lifestyle of countless individuals might be improved through the development of this technology, as it could lead to the discovery and production of bioactive secondary metabolites from microorganisms like Streptomyces, such as the potent antibiotic taromycin A.
- The food-and-drink industry could potentialy benefit from the advancements in biological research, as the understanding of microbes' biosynthetic processes may lead to the development of new compounds with various applications.
- The technology sector, specifically gadgets and technology, might experience growth due to the increased demand for tools that enable the efficient analysis and manipulation of DNA sequences, essential for the application of this TAR cloning technology.
- The education-and-self-development sector could see an increase in offerings related to science, as the public's interest in understanding the intricate workings of microbes and their potential applications in drug discovery is likely to grow.
